Synlogic Inc. said COO and head of corporate development, Andrew Gengos, will leave the company on Jan. 15, 2019.

The company, which agreed to a severance package with Gengos, said in a news release that his employment was "terminated without cause as a result of his role at the company being materially diminished."

Cambridge, Mass.-based Synlogic is a clinical-stage biopharmaceutical company that focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory and cancer diseases.